Acromegaly Enrollment Form



Fax Referral To: 1-800-323-2445

Phone: 1-800-237-2767 Email Referral To: Customer.ServiceFax@CVSHealth.com

Bynfezia Pen (octreotide acetate) injection		Six Simple	Steps to Subn	nitting a Referral			
Address:	PATIENT INFORMATI	ION (Complete or include d	emographic she	et)			
International Content Inte	atient Name:	Name: DOB:					
Institute Male Female Preferred Contact Methods: Phone (to primary # provided below) Text (to cell # provided below) Email (to email provided below) Institute Preferred Contact Methods: Phone (to primary # provided below) Text (to cell # provided below) Institute Preferred Contact Methods: Phone (to primary # provided below) Text (to cell # provided below) Institute Preferred Caregiver Pharmacy will attempt to contact by phone. Pharmacy will attempt to contact by phone. Pharmacy will attempt to contact by phone. Pharmacy will be preferred w	ddress:	City, State, ZIP Code:					
Insurance Contect by phone	ender: 🗌 Male 🔲 Fema			-			
Alternate Phone:	referred Contact Methods	: Phone (to primary # provid	led below) 🗌 Text	to cell # provided belo	w) 🗌 Email (to emai	il provided below)	
Minor, Parent/Caregiver/Guardian Name (Last, First): teleptationship to minor: realt Last Four of SSN: Primary Language: relationship to minor: relationship to minor: State License #: PIF #: DEA #: Group or Hospital: City, State, ZIP Code: City, State, ZIP Code: City, State, ZIP Code: Contact's Phone: C	lote: Carrier charges may appl	y. If unable to contact via text of	r email, Specialty P	harmacy will attempt to	contact by phone.		
PRESCRIBER INFORMATION	rimary Phone:			Alternate Phone:			
PRESCRIBER INFORMATION rescriber's Name: Pit:	Minor, Parent/Caregiver/	Guardian Name (Last, First)	:				
PRESCRIBER INFORMATION PRESCRIBER INFORMATION PRESCRIBER INFORMATION PRESCRIBER INFORMATION PRESCRIBER INFORMATION Page Prescriber's Name: State License #: Pi #:	elationship to minor:						
RESCRIBER INFORMATION State License #:			Last Four	of SSN: Pi	rimary Language: .		
State License #: DEA #: Group or Hospital: Group or	PRESCRIBER INFORM						
PI #: DEA #: Group or Hospital: ddress:				State License #:			
City, State, ZIP Code:							
INSURANCE INFORMATION Please fax copy of prescription and insurance cards with this form, if available (front and back) DIAGNOSIS AND CLINICAL INFORMATION each by Date:	ddress:		c oap c	ity State 7IP Code:			
INSURANCE INFORMATION Please fax copy of prescription and insurance cards with this form, if available (front and back) DIAGNOSIS AND CLINICAL INFORMATION each by Date:	hone:	Fav	Contact Pers	ny, otato, 211 oodo	Contact's Ph	one.	
Ship to:	INSUDANCE INFORM	IATION Places for copy of	procesintian and	Lincurance carde with	this form if avails	ohlo (front and book)	
each by Date:			prescription and	i insurance carus witi	i tilis ioriii, ii avalla	able (Ironi and back)	
E22.0 acromegaly and pituitary giantism		NICAL INFORMATION					
E22.0 acromegaly and pituitary giantism Other Code: Description:	-		Ship to: 🔝	Patient Office	Other:		
Height:in/cm Weight:lb/kg							
PRESCRIPTION INFORMATION STRENGTH DOSE & DIRECTIONS DIRECTIONS DOSE & DIRECTIONS DIRECTIONS DOSE & DOS			☐ Other C	code: Descrip	tion:		
PRESCRIPTION INFORMATION MEDICATION STRENGTH DOSE & DIRECTIONS QUANTITY/REFIL 2 pons Other: mcg SC three times a day Other: Refills: 2 pons Other: mg (1 syringe) SC every 4 weeks 12 mg (1 syringe) SC every 4 weeks 13 mg (1 syringe) SC every 4 weeks 14 mg (1 syringe) SC every 4 weeks 15 mg vial kits 15 mg		<u>n:</u>					
MEDICATION STRENGTH DOSE & DIRECTIONS QUANTITY/REFIL	•		Height:	in/cm	Weight:	lb/kg	
Bynfezia Pen (octreotide locetate) injection	PRESCRIPTION INFO	RMATION					
Syndostatin Injection Cortection Corte	MEDICATION	STRENGTH		DOSE & DIRECTION	S	QUANTITY/REFILLS	
Lanreotide Injection	_ ,	2,500 mcg/mL				☐ Other:	
Sandostatin Injection Ampules	Lanreotide Injection	90 mg prefilled syringe				4-week supply 12-week supply	
Sandostatin Injection 200 mcg/mL (5 ml) Administer mcg SC three times a day Quantity: Refills: Multi-dose Vials 1,000 mcg/mL (5 ml) Other: Mix the contents of one vial with diluent and administer 4-week supply 12-week supply 12	Sandostatin Injection	50 mcg/mL				Quantity:	
Sandostatin Injection 200 mcg/mL (5 ml) Administer mcg SC three times a day Quantity: Refills: 4-week supply 12-week supply 12-	Ampules	_	Other:			rtontio.	
Multi-dose Vials	Sandostatin Injection		Administer	mcg SC three times	a day	Quantity:	
Sandostatin LAR Depot				-	·	Refills:	
Somatuline Depot	Sandostatin LAR Depot	20 mg vial kit	intragluteally eve		ent and administer	12-week supply	
Somavert 15 mg vial 15 mg vial 20 mg vial 20 mg vial 20 mg vial 20 mg vial kits 20 mg vial 20 mg vial kits 20 mg vial 20 mg vial kits 20 mg vial kits	Somatuline Depot	60 mg prefilled syringe 90 mg prefilled syringe				12-week supply	
*Dispense As Written" / Brand Medically Necessary / Do Not Substitute / No Substitution / DAW / May Not Substitute Prescriber's Signature:Date:Date:Date:		10 mg vial 15 mg vial 20 mg vial 25 mg vial 30 mg vial	Other:				
"Dispense As Written" / Brand Medically Necessary / Do Not Substitute / No Substitution / DAW / May Not Substitute Prescriber's Signature:Date:Date:Date:Date:Date:Date:	- · · · · · · · · · · · · · · · · · · ·	. •			, ,,		
DAW / May Not Substitute Prescriber's Signature:Date:	6 PRES	CRIBER SIGNATURE R	EQUIRED (ST	AMP SIGNATUR	E NOT ALLOW	(ED)	
	DAW / May Not Substitute	,		Substitution Permissible		Date:	

The information provided above is true and accurate to the best of my knowledge, with supporting documentation in the patient's medical record. By signing above, I hereby authorize CVS Specialty Pharmacy and/or its affiliate pharmacies to complete and submit prior authorization (PA) requests to payors for the prescribed medication for this patient and to attach this Enrollment Form to the PA

CONFIDENTIALITY NOTICE: This communication and any attachments may contain confidential and/or privileged information for the use of the designated recipients named above. If you are not the intended recipient, you are hereby notified that you have received this communication in error and that any review, disclosure, dissemination, distribution or copying of it or its contents is prohibited. If you have received this communication in error, please notify the sender immediately by telephone and destroy all copies of this communication and any attachments.

Plan member privacy is important to us. Our employees are trained regarding the appropriate way to handle members' private health information.

This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Specialty and/or one of its affiliates. ©2022 CVS Specialty and/or one of its affiliates. 75-47192A 04/06/22